Overview
Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
Indication
No indication information available.
Associated Conditions
- Headache
- Mild pain
- Rhinorrhoea
- Sneezing
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
SEMOR PAIN AND FEVER RELIEF CAPSULES | SIN08055P | CAPSULE | 250 mg | 2/28/1995 | |
CON-Z-LIN TABLET | SIN05768P | TABLET, SUGAR COATED | 250 mg | 4/22/1991 | |
CONSU CAPSULE | SIN02859P | CAPSULE | 250 mg | 5/22/1989 | |
FONGTIT 600 CAPSULE | SIN03369P | CAPSULE | 250 mg | 6/17/1989 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
HUNFANINE CAP | N/A | karen laboratories o/b karen pharmaceutical co ltd | N/A | N/A | 10/31/1996 |
PANCOL CAP | N/A | synco (h.k.) limited | N/A | N/A | 2/15/2008 |
COLIDIN TAB | N/A | N/A | N/A | 1/13/1989 | |
POURKE CAP | N/A | N/A | N/A | 6/9/2006 | |
SANBRON CAP | N/A | N/A | N/A | 1/21/1999 | |
IGLOIE CAP | N/A | N/A | N/A | 7/30/2006 | |
FIRMBO CAP | N/A | N/A | N/A | 6/9/2006 | |
COLDTOP-FORTE CAP | N/A | N/A | N/A | 7/15/2006 | |
NICHOCOSIN CAP | N/A | synco (h.k.) limited | N/A | N/A | 3/15/2008 |
PROSCO CAP | N/A | N/A | N/A | 1/21/1999 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
YENDOL GRANULADO PARA SUSPENSION ORAL | 47802 | GRANULADO PARA SUSPENSIÓN ORAL | Sin Receta | Commercialized | |
RINOMICINE COMPRIMIDOS RECUBIERTOS | Laboratorio De Aplicaciones Farmacodinamicas S.A. | 48578 | COMPRIMIDO RECUBIERTO CON PELÍCULA | Sin Receta | Not Commercialized |
RINOMICINE POLVO PARA SUSPENSIÓN ORAL | Laboratorio De Aplicaciones Farmacodinamicas S.A. | 56526 | POLVO PARA SUSPENSIÓN ORAL | Sin Receta | Commercialized |
RINOMICINE COMPRIMIDOS | Laboratorio De Aplicaciones Farmacodinamicas S.A. | 42550 | COMPRIMIDO | Sin Receta | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.